FDA
-
-
-
-
-
-
-
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
-
-
-
-
-
-
-
Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
322,173 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

